FOLD - Amicus Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Philadelphia,
United States
Type: Equity
FOLD price evolution
FOLD
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $209.34 | $209.76 | $246.99 | |
| Short term investments | $50.73 | $29.84 | $39.21 | |
| Net receivables | $98.07 | $85.17 | $76.43 | $87.63 |
| Inventory | $115.34 | $81.32 | $60.76 | $59.7 |
| Total current assets | $498.47 | $461.7 | $431.24 | $483.06 |
| Long term investments | ||||
| Property, plant & equipment | $53.58 | $53.77 | $55.42 | $57.98 |
| Goodwill & intangible assets | $216.65 | $217.47 | $218.29 | |
| Total noncurrent assets | $287.78 | $290.55 | $294.82 | |
| Total investments | $50.73 | $29.84 | $39.21 | |
| Total assets | $786.56 | $749.48 | $721.79 | $777.88 |
| Current liabilities | ||||
| Accounts payable | $13.48 | $32.06 | $9.21 | $15.12 |
| Deferred revenue | ||||
| Short long term debt | $8.11 | $8.27 | $8.32 | |
| Total current liabilities | $158.14 | $168.07 | $142.1 | $167.69 |
| Long term debt | $389.49 | $388.94 | $388.39 | $436.74 |
| Total noncurrent liabilities | $448.89 | $448.99 | $450.02 | |
| Total debt | $444.06 | $444.49 | $445.06 | |
| Total liabilities | $607.73 | $616.96 | $591.1 | $617.71 |
| Shareholders' equity | ||||
| Retained earnings | -$2754.85 | -$2748.12 | -$2732.42 | -$2684.07 |
| Other shareholder equity | $25.16 | $8.99 | $6.85 | $5.24 |
| Total shareholder equity | $132.52 | $130.69 | $160.17 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $246.99 | $148.81 | $245.2 | $163.24 |
| Short term investments | $39.21 | $144.78 | $237.3 | $320.03 |
| Net receivables | $87.63 | $66.2 | $52.67 | $46.92 |
| Inventory | $59.7 | $23.82 | $26.82 | $19.56 |
| Total current assets | $483.06 | $423.82 | $596.83 | $579.47 |
| Long term investments | ||||
| Property, plant & equipment | $57.98 | $60.31 | $63.08 | $67.16 |
| Goodwill & intangible assets | $218.29 | $197.8 | $197.8 | $197.8 |
| Total noncurrent assets | $294.82 | $300.35 | $308.31 | $307.05 |
| Total investments | $39.21 | $144.78 | $237.3 | $320.03 |
| Total assets | $777.88 | $724.17 | $905.14 | $886.52 |
| Current liabilities | ||||
| Accounts payable | $15.12 | $15.41 | $41.85 | $42.89 |
| Deferred revenue | ||||
| Short long term debt | $8.32 | $8.55 | $7.41 | $6.87 |
| Total current liabilities | $167.69 | $139.02 | $145.97 | $129.68 |
| Long term debt | $436.74 | $391.99 | $432.72 | $434.86 |
| Total noncurrent liabilities | $450.02 | $462.1 | $451.8 | $470.46 |
| Total debt | $445.06 | $452.12 | $440.13 | $441.73 |
| Total liabilities | $617.71 | $601.12 | $597.77 | $600.14 |
| Shareholders' equity | ||||
| Retained earnings | -$2684.07 | -$2532.41 | -$2295.92 | -$2045.46 |
| Other shareholder equity | $5.24 | -$11.99 | $4.98 | $8.23 |
| Total shareholder equity | $160.17 | $123.05 | $307.37 | $286.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $141.52 | $126.67 | $110.4 | $115.08 |
| Cost of revenue | $11.26 | $13.57 | $11.32 | |
| Gross Profit | $128.24 | $115.41 | $96.84 | $103.76 |
| Operating activities | ||||
| Research & development | $24.68 | $28.33 | $35.03 | |
| Selling, general & administrative | $73.58 | $88.03 | $70.24 | |
| Total operating expenses | $103.44 | $104.16 | $129.52 | $107.45 |
| Operating income | $11.25 | -$32.69 | -$3.69 | |
| Income from continuing operations | ||||
| EBIT | $12.62 | -$31.15 | -$18.83 | |
| Income tax expense | $13.51 | $15.8 | $4.84 | $2.18 |
| Interest expense | -$11.61 | $12.51 | $12.44 | $12.83 |
| Net income | ||||
| Net income | -$6.73 | -$15.7 | -$48.42 | -$33.84 |
| Income (for common shares) | -$15.7 | -$48.42 | -$33.84 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $399.36 | $329.23 | $305.51 | $260.89 |
| Cost of revenue | $37.33 | $38.6 | $34.47 | $31.04 |
| Gross Profit | $362.03 | $290.63 | $271.05 | $229.84 |
| Operating activities | ||||
| Research & development | $152.38 | $276.68 | $272.05 | $308.44 |
| Selling, general & administrative | $275.27 | $213.04 | $192.71 | $156.41 |
| Total operating expenses | $436.66 | $501.68 | $470.97 | $473.7 |
| Operating income | -$74.63 | -$211.04 | -$199.92 | -$243.85 |
| Income from continuing operations | ||||
| EBIT | -$99.95 | -$204.92 | -$209.08 | -$251.83 |
| Income tax expense | $1.48 | -$5.47 | $8.91 | $2.6 |
| Interest expense | $50.15 | $37.12 | $32.47 | $22.43 |
| Net income | ||||
| Net income | -$151.58 | -$236.57 | -$250.46 | -$276.85 |
| Income (for common shares) | -$151.58 | -$236.57 | -$250.46 | -$276.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$15.7 | -$48.42 | -$33.84 | |
| Operating activities | ||||
| Depreciation | $2.18 | $2.15 | $2.18 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.2 | $30.8 | $18.09 | |
| Total cash flows from operations | $22.69 | -$29.7 | $3.46 | |
| Investing activities | ||||
| Capital expenditures | -$1.1 | -$1.81 | -$1.73 | |
| Investments | -$20.88 | $9.35 | -$22.23 | |
| Total cash flows from investing | $19.83 | -$21.98 | $7.54 | -$23.96 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.86 | $3.45 | $32.24 | |
| Net borrowings | -$0.04 | -$0.04 | -$20.88 | |
| Total cash flows from financing | $4.02 | -$0.86 | -$13.31 | $8.21 |
| Effect of exchange rate | -$7.14 | -$0.29 | -$1.82 | -$3.91 |
| Change in cash and equivalents | -$13.26 | -$0.44 | -$37.28 | -$16.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$151.58 | -$236.57 | -$250.46 | -$276.85 |
| Operating activities | ||||
| Depreciation | $7.87 | $5.34 | $6.21 | $8.85 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $86.08 | $76.51 | $57.84 | $49.15 |
| Total cash flows from operations | -$69.09 | -$166.57 | -$202.49 | -$233.29 |
| Investing activities | ||||
| Capital expenditures | -$7.44 | -$0.35 | -$3.88 | -$3.23 |
| Investments | $105.5 | $92.67 | $82.64 | -$10.35 |
| Total cash flows from investing | $98.06 | $92.32 | $78.76 | -$13.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $103.21 | -$7.18 | $229.21 | $32.25 |
| Net borrowings | -$20.96 | -$0.28 | -$0.48 | $230.6 |
| Total cash flows from financing | $61.68 | -$7.46 | $212.07 | $262.86 |
| Effect of exchange rate | $6.31 | -$14.62 | -$5.05 | $3.83 |
| Change in cash and equivalents | $96.96 | -$96.34 | $83.29 | $19.82 |
News
Fundamentals
| Market cap | $2.90B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 298.69M |
| Revenue | $493.67M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$104.69M |
| Revenue Q/Q | 36.73% |
| Revenue Y/Y | 32.58% |
| P/E ratio | -27.73 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.88 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.35 |
|---|---|
| ROA | -13.79% |
| ROE | N/A |
| Debt/Equity | 3.86 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.15 |
| Quick ratio | 2.42 |